Link to this page
Drug Target Ontology
Last uploaded:
February 15, 2018
| Acronym | DTO |
| Visibility | Public |
| Description | Drug Target Ontology (DTO) is being developed at the University of Miami in the research group of Stephan Schürer. DTO is supported by grant U54CA189205 (Illuminating the Druggable Genome Knowledge Management Center, Tudor Oprea, PI) awarded by the NCI through the NIH Common Fund. It is a component of the Illuminating the Druggable Genome (IDG) project (https://commonfund.nih.gov/idg). The DTO project develops a novel semantic framework to formalize knowledge about drug targets with a focus on the current IDG protein families. The DTO is developed as a reference for drug targets with the longer-term goal to create a community standard that will facilitate the integration of diverse drug discovery information from numerous heterogeneous resources. The first version of the DTO consists of asserted class hierarchies of the four IDG protein families, GPCRs, kinases, ion channels, and nuclear hormone receptors. Protein classes are linked to tissue and disease via different levels of confidence. DTO also contains drug target development level classifications developed in the IDG project (http://targetcentral.ws/), and functional and qualitative annotations and classifications for kinase proteins, GPCR ligands and ion channels. DTO is modeled in OWL2-DL to enable further classification by inference reasoning and SPARQL queries. DTO is implemented following a modularization approach. DTO is used as the organizational framework for drug targets in the IDG PHAROS User Interface Portal (https://pharos.nih.gov) and also the Tin-X Target Importance and Novelty Explorer (http://newdrugtargets.org). |
| Status | Beta |
| Format | OWL |
| Contact | Stephan Schurer, sschurer@med.miami.edu |
| Categories | Chemical, Gene Product, Human, Molecule, Other, Protein |
| License Information | This ontology is licensed under Creative Commons Attribution-ShareAlike 4.0 International. |
| Version | Released | Uploaded | Downloads |
|---|---|---|---|
| 1.1.1 (Parsed, Indexed, Metrics, Annotator) | 02/15/2018 | 02/15/2018 | OWL | CSV | RDF/XML | Diff |
| 1.1 (Archived) | 12/07/2017 | 12/07/2017 | OWL | Diff |
| 1.1 (Archived) | 12/06/2017 | 12/06/2017 | OWL | Diff |
| 1.0 (Archived) | 07/20/2017 | 07/20/2017 | OWL | Diff |
| 1.0 (Archived) | 12/04/2015 | 12/04/2015 | OWL |
| more... | |||
No views of DTO available
| Classes | 10,075 |
| Individuals | 3 |
| Properties | 43 |
| Maximum depth | 0 |
| Maximum number of children | 1,691 |
| Average number of children | 4 |
| Classes with a single child | 1,278 |
| Classes with more than 25 children | 30 |
| Classes with no definition | 3,290 |
Jump to:
| Id | http://purl.obolibrary.org/obo/DOID_0060173
http://purl.obolibrary.org/obo/DOID_0060173
|
|---|---|
| Preferred Name | Timothy syndrome |
| Definitions |
An autosomal dominant disease that is characterized by cardiac, hand/foot, facial, and neurodevelopmental features. The two forms are type 1 (classic) and type 2, a rare form that has_material_basis_in mutations in a transcript variant of CACNA1C on chromosome 12p13.33.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An autosomal dominant disease that is characterized by cardiac, hand/foot, facial, and neurodevelopmental features. The two forms are type 1 (classic) and type 2, a rare form that has_material_basis_in mutations in a transcript variant of CACNA1C on chromosome 12p13.33. |
|---|---|
| label | Timothy syndrome
|
| prefLabel | Timothy syndrome
|
| hasOBONamespace | disease_ontology
|
| creation_date | 2011-11-08T12:52:33Z
|
| created_by | lschriml
|
| prefixIRI | DOID:0060173
|
| subClassOf | |
| imported from | |
| hasDbXref |
OMIM:601005
ICD10CM:G72.3
ORDO:65283
ORDO:768
|
| hasAlternativeId | DOID:0110649
|
| type | |
| id | DOID:0060173
|
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |
- Problem retrieving properties:
Notes
Filter: